Heart failure in Sub-Saharan Africa

Current Cardiology Reviews

Volumn 9, Issue 2, 2013, Pages 157-173

  Bloomfield, Gerald S ^a,b   Barasa, Felix A ^c   Doll, Jacob A ^a   Velazquez, Eric J ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c MOI TEACHING AND REFERRAL HOSPITAL   (Kenya)

Author keywords

Heart failure; Sub Saharan Africa

Indexed keywords

AFRICA SOUTH OF THE SAHARA; AGING; CARDIOMYOPATHY; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; COR PULMONALE; ENVIRONMENT; HABIT; HEALTH CARE; HEART DISEASE; HEART FAILURE; HEART MUSCLE FIBROSIS; HISTORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; LIFESTYLE; PATHOPHYSIOLOGY; PERICARDIAL DISEASE; PRIORITY JOURNAL; REVIEW; RHEUMATIC HEART DISEASE; URBANIZATION; CLASSIFICATION; COMORBIDITY; EPIDEMIOLOGY; HEART MUSCLE ISCHEMIA; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; CARDIOMYOPATHIES; ENDOMYOCARDIAL FIBROSIS; HIV INFECTIONS; MYOCARDIAL ISCHEMIA; PULMONARY HEART DISEASE;

AFRICA SOUTH OF THE SAHARA; CARDIOMYOPATHIES; CAUSALITY; COMORBIDITY; ENDOMYOCARDIAL FIBROSIS; HEART FAILURE; HIV INFECTIONS; HUMANS; HYPERTENSION; MYOCARDIAL ISCHEMIA; PULMONARY HEART DISEASE; RHEUMATIC HEART DISEASE;

EID: 84887999388     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/1573403X11309020008     Document Type: Review

References (228)

1. Khatibzadeh S, Farzadfar F, Oliver J, Ezzati M, Moran A. Worldwide risk factors for heart failure: A systematic review and pooled analysis. Int J Cardiol 2012.
2. Schocken DD, Benjamin EJ, Fonarow GC, et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008; 117(19): 2544-2565.
3. Damasceno A, Cotter G, Dzudie A, Sliwa K, Mayosi BM. Heart failure in sub-saharan Africa: time for action. J Am Coll Cardiol 2007; 50(17): 688-693.
4. Amoah AG, Kallen C. Aetiology of heart failure as seen from a National Cardiac Referral Centre in Africa. Cardiology 2000; 93(1-2): 11-18.
5. Mendez GF, Cowie MR. The epidemiological features of heart failure in developing countries: a review of the literature. Int J Car-diol. 2001; 80(2-3):213-219.
6. Damasceno A, Mayosi BM, Sani M, et al. The Causes, Treatment, and Outcome of Acute Heart Failure in 1006 Africans From 9 Countries: Results of the Sub-Saharan Africa Survey of Heart Failure. Arch Intern Med 2012: 1-9.
7. Shaper AG, Williams AW. Cardiovascular disorders at an African hospital in Uganda. Trans R Soc Trop Med Hyg 1960; 54: 12-32.
8. Gelfand M. Heart disease in the elderly African. Br Heart J 1961; 23: 387-392.
9. Bradlow B, Zion M, Fleishman S. Heart disease in Africa, with particular reference to Southern Africa. Am J Cardiol 1964; 13: 650-669.
10. Chesler E, Mitha AS, Weir EK, Matisonn RE, Hitchcock PJ. Myo-cardial infarction in the black population of South Africa: coronary arteriographic findings. Am Heart J 1978; 95(6): 691-696.
11. Sliwa K, Wilkinson D, Hansen C, et al. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. Lancet 2008; 371(9616): 915-922.
12. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005; 330(7492): 625.
13. Kingue S, Dzudie A, Menanga A, Akono M, Ouankou M, Muna W. [A new look at adult chronic heart failure in Africa in the age of the Doppler echocardiography: experience of the medicine department at Yaounde General Hospital]. Ann Cardiol Angeiol (Paris) 2005; 54(5): 276-283.
14. Adewole AD, Ikem RT, Adigun AQ, Akintomide AO, Balogun MO, Ajayi AA. A three year clinical review of the impact of angio-tensin converting enzyme inhibitors on the intra hospital mortality of congestive heart failure in Nigerians. Cent Afr J Med 1996;42(8):253-255.
15. Kengne AP, Dzudie A, Sobngwi E. Heart failure in sub-Saharan Africa: a literature review with emphasis on individuals with diabetes. Vasc Health Risk Manag 2008; 4(1): 123-130.
16. Nabel EG, Stevens S, Smith R. Combating chronic disease in developing countries. Lancet 2009; 373(9680): 2004-2006.
17. Daar AS, Singer PA, Persad DL, et al. Grand challenges in chronic non-communicable diseases. Nature 2007; 450(7169): 494-496.
18. Stewart S, Wilkinson D, Hansen C, et al. Predominance of heart failure in the Heart of Soweto Study cohort: emerging challenges for urban African communities. Circulation 2008; 118(23): 2360-2367.
19. Sliwa K, Carrington M, Mayosi BM, Zigiriadis E, Mvungi R, Stewart S. Incidence and characteristics of newly diagnosed rheumatic heart disease in urban African adults: insights from the heart of Soweto study. Eur Heart J 2010; 31(6): 719-727.
20. Ntusi NBA, Mayosi BM. Epidemiology of heart failure in sub-Saharan Africa. Expert Rev Cardiovasc Ther 2009; 7(2): 169-180.
21. Essop MR, Nkomo VT. Rheumatic and nonrheumatic valvular heart disease: epidemiology, management, and prevention in Africa. Circulation 2005; 112(23): 3584-3591.
22. World Health Organization. WHO Expert Consultation on Rheumatic Fever and Rheumatic Heart Disease. Technical Report Series 923. Geneva, Switzerland: 2004.
23. Beaton A, Okello E, Lwabi P, Mondo C, McCarter R, Sable C. Echocardiography screening for rheumatic heart disease in ugandan schoolchildren. Circulation 2012; 125(25): 3127-3132.
24. Marijon E, Ou P, Celermajer DS, et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med 2007; 357(5): 470-476.
25. Bhaya M, Panwar S, Beniwal R, Panwar RB. High prevalence of rheumatic heart disease detected by echocardiography in school children. Echocardiography 2010; 27(4): 448-453.
26. Anabwani GM, Book W, Bonhoeffer P. Echocardiographic findings in Eldoret: retrospective study. East Afr Med J 1996; 73(11): 714-716.
27. Rowe JC, Bland EF, Sprague HB, White PD. The course of mitral stenosis without surgery: ten- and twenty-year perspectives. Ann Intern Med 1960; 52: 741-749.
28. OLESEN KH. The natural history of 271 patients with mitral stenosis under medical treatment. Br Heart J 1962; 24: 349-357.
29. Grant RT. The Prognosis of Heart Disease. Bull N Y Acad Med 1933; 9(8): 500-502.
30. Oli K, Asmera J. Rheumatic heart disease in Ethiopia: could it be more malignant? Ethiop Med J 2004; 42(1): 1-8.
31. Strasser T, Dondog N, El Kholy A, et al. The community control of rheumatic fever and rheumatic heart disease: report of a WHO international cooperative project. Bull World Health Organ 1981; 59(2): 285-294.
32. Mayosi B, Robertson K, Volmink J, et al. The Drakensberg declaration on the control of rheumatic fever and rheumatic heart disease in Africa. S Afr Med J 2006; 96(3 Pt 2): 246.
33. Chiang CW, Lo SK, Ko YS, Cheng NJ, Lin PJ, Chang CH. Predictors of systemic embolism in patients with mitral stenosis. A prospective study. Ann Intern Med. 1998;128(11):885-889.
34. Reményi B, Wilson N, Steer A, et al. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease--an evidence-based guideline. Nat Rev Cardiol 2011; 9(5): 297-309.
35. Manyemba J, Mayosi BM. Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst Rev 2002(3): CD002227.
36. Cilliers A, Manyemba J, Adler AJ, Saloojee H. Anti-inflammatory treatment for carditis in acute rheumatic fever. Cochrane Database Syst Rev 2012; 6: CD003176.
37. Karthikeyan G, Mayosi BM. Is primary prevention of rheumatic fever the missing link in the control of rheumatic heart disease in Africa? Circulation 2009; 120(8): 709-713.
38. McLaren MJ, Markowitz M, Gerber MA. Rheumatic heart disease in developing countries: the consequence of inadequate prevention. Ann Intern Med 1994; 120(3): 243-245.
39. Cappuccio FP, Micah FB, Emmett L, et al. Prevalence, detection, management, and control of hypertension in Ashanti, West Africa. Hypertension 2004; 43(5): 1017-1022.
40. Steyn K, Gaziano TA, Bradshaw D, Laubscher R, Fourie J, Team SADaHC. Hypertension in South African adults: results from the Demographic and Health Survey, 1998. J Hypertens 2001; 19(10): 1717-1725.
41. de Ramirez SS, Enquobahrie DA, Nyadzi G, et al. Prevalence and correlates of hypertension: a cross-sectional study among rural populations in sub-Saharan Africa. J Hum Hypertens 2010; 24(12): 786-795.
42. Mathenge W, Foster A, Kuper H. Urbanization, ethnicity and cardiovascular risk in a population in transition in Nakuru, Kenya: a population-based survey. BMC Public Health 2010; 10(1): 569.
43. Ibrahim MM, Damasceno A. Hypertension in developing countries. Lancet 2012; 380(9841): 611-619.
44. Opie LH. Heart disease in Africa. Lancet 2006; 368(9534): 449-450.
45. Frohlich ED. State of the Art lecture. Risk mechanisms in hypertensive heart disease. Hypertension 1999; 34(4 Pt 2): 782-789.
46. Fuchs FD. Why do black Americans have higher prevalence of hypertension?: an enigma still unsolved. Hypertension 2011; 57(3): 379-380.
47. Gelfand M. The Sick African. 2nd ed. Cape Town: Juta; 1957.
48. Schwartz M, Schamroth L, Seftel H. The pattern of heart disease in the urbanized Johannesburg African. Med Proc 1958; 4: 275.
49. Cosnett JE. Heart disease in the Zulu: especially cardiomyopathy and cardiac infarction. Br Heart J 1962; 24: 76-82.
50. Baldachin BJ. Cardiovascular disease in the african in matabele-land. Cent Afr J Med 1963; 28: 463-469.
51. Powell SJ, Wright R. Cardiomyopathy in Durban. S Afr Med J 1965; 39(42): 1062-1066.
52. Brown KG, Willis WH. Cardiac disease in Malawi. S Afr Med J 1975; 49(23): 926-930.
53. Ladipo GO, Froude JR, Parry EH. Pattern of heart disease in adults of the Nigerian Savanna: a prospective clinical study. Afr J Med Med Sci 1977; 6(4): 185-192.
54. Abengowe CU. Cardiovascular disease in Northern Nigeria. Trop Geogr Med 1979; 31(4): 553-560.
55. Antony KK. Pattern of cardiac failure in Northern Savanna Nigeria. Trop Geogr Med 1980; 32(2): 118-125.
56. Maharaj B. Causes of congestive heart failure among black patients at King Edward VIII hospital, Durban. Cardiovasc J Southern Africa 1991; 2(1): 31-32.
57. Lodenyo HA, McLigeyo SO, Ogola EN. Cardiovascular disease in elderly in-patients at the Kenyatta National Hospital, Nairobi-Kenya. East African Med J 1997; 74(10): 647-651.
58. Hakim JG, Manyemba J. Cardiac disease distribution among patients referred for echocardiography in Harare, Zimbabwe. Cent Afr J Med 1998; 44(6): 140-144.
59. Oyoo GO, Ogola EN. Clinical and socio demographic aspects of congestive heart failure patients at Kenyatta National Hospital, Nairobi. East African Med J 1999; 76(1): 23-27.
60. Thiam M. Cardiac insufficiency in the African cardiology milieu. Bull Soc Pathol Exot 2003; 96(3): 217-218.
61. Owusu IK. Causes of heart failure as seen in Kumasi, Ghana. The Int J Third World Med 2007; 5(1): 1-10.
62. Familoni OB, Olunuga TO, Olufemi BW. A clinical study of pattern and factors affecting outcome in Nigerian patients with advanced heart failure. Cardiovasc J Afr 2007; 18(5): 308-311.
63. Ismail Y, Andia I, Byaruhanga S, Shaw MR, Mathieson PW, Wilde P. Echocardiographic features of cardiac failure in Uganda. Trop Doct 2007; 37(4): 267-268.
64. Onwuchekwa AC, Asekomeh GE. Pattern of heart failure in a Nigerian teaching hospital. Vasc Health Risk Manag 2009; 5: 745-750.
65. Ojji DB, Alfa J, Ajayi SO, Mamven MH, Falase AO. Pattern of heart failure in Abuja, Nigeria: an echocardiographic study. Car-diovasc J Afr 2009; 20(6): 349-352.
66. Tantchou Tchoumi JC, Ambassa JC, Kingue S, et al. Occurrence, aetiology and challenges in the management of congestive heart failure in sub-Saharan Africa: experience of the Cardiac Centre in Shisong, Cameroon. Pan Afr Med J 2011; 8: 11.
67. Drazner MH. The progression of hypertensive heart disease. Circulation 2011; 123(3): 327-334.
68. Gasperin CA, Germiniani H, Facin CR, Souza AM, Cunha CL. An analysis of electrocardiographic criteria for determining left ventricular hypertrophy. Arq Bras Cardiol 2002; 78(1): 59-82.
69. Lip GY, Felmeden DC, Li-Saw-Hee FL, Beevers DG. Hypertensive heart disease. A complex syndrome or a hypertensive 'cardio-myopathy'? Eur Heart J 2000; 21(20): 1653-1665.
70. Cabezas M, Comellas A, Ramón Gómez J, et al. Comparison of the sensitivity and specificity of the electrocardiography criteria for left ventricular hypertrophy according to the methods of Romhilt-Estes, Sokolow-Lyon, Cornell and Rodríguez Padial. Rev Esp Cardiol 1997; 50(1): 31-35.
71. Levy D, Labib SB, Anderson KM, Christiansen JC, Kannel WB, Castelli WP. Determinants of sensitivity and specificity of electro-cardiographic criteria for left ventricular hypertrophy. Circulation 1990; 81(3): 815-820.
72. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57(6): 450-458.
73. Gluba A, Bielecka A, Mikhailidis DP, et al. An update on bio-markers of heart failure in hypertensive patients. J Hypertens 2012; 30(9): 1681-1689.
74. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53(15): e1-e90.
75. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996; 275(19): 1507-1513.
76. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41(9): 1529-1538.
77. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358(9290): 1305-1315.
78. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560-2572.
79. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981-2997.
80. Peacock F, Amin A, Granger CB, et al. Hypertensive heart failure: patient characteristics, treatment, and outcomes. Am J Emerg Med 2011; 29(8): 855-862.
81. Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis. Circulation 2005; 112(23): 3608-3616.
82. Ntsekhe M, Mayosi BM. Tuberculous pericarditis with and without HIV. Heart Fail Rev 2012.
83. Sagristà-Sauleda J, Mercé AS, Soler-Soler J. Diagnosis and management of pericardial effusion. World J Cardiol 2011; 3(5): 135-143.
84. Sheth S, Wang DD, Kasapis C. Current and emerging strategies for the treatment of acute pericarditis: a systematic review. J Inflamm Res 2010; 3: 135-142.
85. Reuter H, Burgess LJ, Doubell AF. Epidemiology of pericardial effusions at a large academic hospital in South Africa. Epidemiol Infect 2005; 133(3): 393-399.
86. Mayosi BM, Wiysonge CS, Ntsekhe M, et al. Mortality in patients treated for tuberculous pericarditis in sub-Saharan Africa. S Afr Med J 2008; 98(1): 36-40.
87. Lestuzzi C. Neoplastic pericardial disease: Old and current strategies for diagnosis and management. World J Cardiol 2010; 2(9): 270-279.
88. Roy CL, Minor MA, Brookhart MA, Choudhry NK. Does this patient with a pericardial effusion have cardiac tamponade? JAMA 2007; 297(16): 1810-1818.
89. Reuter H, Burgess LJ, Doubell AF. Role of chest radiography in diagnosing patients with tuberculous pericarditis. Cardiovasc J S Afr 2005; 16(2): 108-111.
90. Lange RA, Hillis LD. Clinical practice. Acute pericarditis. N Engl J Med 2004; 351(21): 2195-2202.
91. Mercé J, Sagristà-Sauleda J, Permanyer-Miralda G, Soler-Soler J. Should pericardial drainage be performed routinely in patients who have a large pericardial effusion without tamponade? Am J Med 1998; 105(2): 106-109.
92. Mayosi BM. Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa. Heart (British Cardiac Society) 2007; 93(10): 1176-1183.
93. Heller T, Lessells RJ, Wallrauch C, Brunetti E. Tuberculosis pericarditis with cardiac tamponade: management in the resource-limited setting. Am J Trop Med Hyg 2010; 83(6): 1311-1314.
94. Seferovic PM, Ristic AD, Maksimovic R, Tatic V, Ostojic M, Kanjuh V. Diagnostic value of pericardial biopsy: improvement with extensive sampling enabled by pericardioscopy. Circulation 2003; 107(7): 978-983.
95. Mayosi BM, Ntsekhe M, Bosch J, et al. Rationale and design of the Investigation of the Management of Pericarditis (IMPI) trial: a 2 x 2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis. Am Heart J 2013; 165(2): 109-115.e3.
96. Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation 2005; 112(13): 2012-2016.
97. Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. N Engl J Med 2011; 364(17): 1643-1656.
98. Dellefave L, McNally EM. The genetics of dilated cardiomyopathy. Curr Opin Cardiol 2010; 25(3): 198-204.
99. Khogali SS, Mayosi BM, Beattie JM, McKenna WJ, Watkins H, Poulton J. A common mitochondrial DNA variant associated with susceptibility to dilated cardiomyopathy in two different populations. Lancet 2001; 357(9264): 1265-1267.
100. Fogle RL, Lynch CJ, Palopoli M, Deiter G, Stanley BA, Vary TC. Impact of chronic alcohol ingestion on cardiac muscle protein expression. Alcohol Clin Exp Res 2010; 34(7): 1226-1234.
101. Lee WK, Regan TJ. Alcoholic cardiomyopathy: is it dose-dependent? Congest Heart Fail 2002; 8(6): 303-306.
102. Klatsky AL. Alcohol and cardiovascular diseases: a historical overview. Ann N Y Acad Sci 2002; 957: 7-15.
103. Patel VB, Why HJ, Richardson PJ, Preedy VR. The effects of alcohol on the heart. Adverse Drug React Toxicol Rev 1997; 16(1): 15-43.
104. Mayosi BM, Somers K. Cardiomyopathy in Africa: heredity versus environment. Cardiovasc J Afr 2007; 18(3): 175-179.
105. Skudicky D, Sliwa K, Bergemann A, Candy G, Sareli P. Reduction in Fas/APO-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated car-diomyopathy treated with pentoxifylline. Heart 2000; 84(4): 438-439.
106. Sanderson JE, Olsen EG, Gatei D. Dilated cardiomyopathy and myocarditis in Kenya: an endomyocardial biopsy study. Int J Car-diol 1993; 41(2): 157-163.
107. Zorai A, Harteveld CL, Rachdi R, et al. Frequency and spectrum of hemochromatosis mutations in Tunisia. Hematol J 2003; 4(6): 433-435.
108. Kotze MJ, de Villiers JN, Bouwens CS, et al. Molecular diagnosis of hereditary hemochromatosis: application of a newly-developed reverse-hybridization assay in the South African population. Clin Genet 2004; 65(4): 317-321.
109. Gangaidzo IT, Moyo VM, Saungweme T, et al. Iron overload in urban Africans in the 1990s. Gut. 1999; 45(2): 278-283.
110. Gordeuk V, Mukiibi J, Hasstedt SJ, et al. Iron overload in Africa. Interaction between a gene and dietary iron content. N Engl J Med 1992; 326(2): 95-100.
111. Murphy CJ, Oudit GY. Iron-overload cardiomyopathy: pathophysi-ology, diagnosis, and treatment. J Card Fail 2010; 16(11): 888-900.
112. Brar SS, Khan SS, Sandhu GK, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol 2007; 100(2): 302-304.
113. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010; 12(8): 767-778.
114. Walenta K, Schwarz V, Schirmer SH, et al. Circulating microparti-cles as indicators of peripartum cardiomyopathy. Eur Heart J 2012; 33(12): 1469-1479.
115. Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bro-mocriptine in the treatment of acute severe peripartum cardiomy-opathy: a proof-of-concept pilot study. Circulation 2010; 121(13): 1465-1473.
116. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomy-opathy. Cell 2007; 128(3): 589-600.
117. Kindermann I, Barth C, Mahfoud F, et al. Update on myocarditis. J Am Coll Cardiol 2012; 59(9): 779-792.
118. Sliwa K, Forster O, Zhanje F, Candy G, Kachope J, Essop R. Outcome of subsequent pregnancy in patients with documented peri-partum cardiomyopathy. Am J Cardiol 2004; 93(11): 1441-1443, A10.
119. Gujja P, Rosing DR, Tripodi DJ, Shizukuda Y. Iron overload car-diomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol 2010; 56(13): 1001-1012.
120. Guillo P, Mansourati J, Maheu B, et al. Long-term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence. Am J Cardiol 1997; 79(9): 1276-1278.
121. Prazak P, Pfisterer M, Osswald S, Buser P, Burkart F. Differences of disease progression in congestive heart failure due to alcoholic as compared to idiopathic dilated cardiomyopathy. Eur Heart J 1996; 17(2): 251-257.
122. Triant VA. HIV infection and coronary heart disease: an intersection of epidemics. J Infect Dis 2012; 205 Suppl 3: S355-S361.
123. Twagirumukiza M, Nkeramihigo E, Seminega B, Gasakure E, Boccara F, Barbaro G. Prevalence of dilated cardiomyopathy in HIV-infected African patients not receiving HAART: a multicen-ter, observational, prospective, cohort study in Rwanda. Curr HIV Res 2007; 5(1): 129-137.
124. Khunnawat C, Mukerji S, Havlichek D, Touma R, Abela GS. Cardiovascular manifestations in human immunodeficiency virus-infected patients. Am J Cardiol 2008; 102(5): 635-642.
125. Rerkpattanapipat P, Wongpraparut N, Jacobs LE, Kotler MN. Cardiac manifestations of acquired immunodeficiency syndrome. Arch Intern Med 2000; 160(5): 602-608.
126. Currie PF, Goldman JH, Caforio AL, et al. Cardiac autoimmunity in HIV related heart muscle disease. Heart 1998; 79(6): 599-604.
127. Barbaro G. Pathogenesis of HIV-associated heart disease. AIDS. 2003; 17 Suppl 1: S12-S20.
128. Longo-Mbenza B, Seghers KV, Phuati M, Bikangi FN, Mubagwa K. Heart involvement and HIV infection in African patients: determinants of survival. Int J Cardiol 1998; 64(1): 63-73.
129. Nzuobontane D, Blackett KN, Kuaban C. Cardiac involvement in HIV infected people in Yaounde, Cameroon. Postgrad Med J 2002; 78(925): 678-681.
130. Currie PF, Jacob AJ, Foreman AR, Elton RA, Brettle RP, Boon NA. Heart muscle disease related to HIV infection: prognostic implications. BMJ 1994; 309(6969): 1605-1607.
131. Ntsekhe M, Mayosi BM. Cardiac manifestations of HIV infection: an African perspective. Nature clinical practice Cardiovasc Med 2009; 6(2): 120-127.
132. Longo-Mbenza B, Tonduangu K, Kintonki Vita E, Seghers KV. The effect of HIV infection on high incidence of heart diseases in Kinshasa (Zaire). Echocardiographic study. Ann Cardiol Angeiol (Paris) 1997; 46(2): 81-87.
133. Bouramoue C, Ekoba J. The heart and AIDS. Med Trop (Mars). 1996; 56(3 Suppl): 33-39.
134. Longo-Mbenza B, Seghers LV, Vita EK, Tonduangu K, Bayekula M. Assessment of ventricular diastolic function in AIDS patients from Congo: a Doppler echocardiographic study. Heart 1998; 80(2): 184-189.
135. Hakim JG, Matenga JA, Siziya S. Myocardial dysfunction in human immunodeficiency virus infection: an echocardiographic study of 157 patients in hospital in Zimbabwe. Heart 1996; 76(2): 161-165.
136. WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-Related Disease in Adults and Children. France: World Health Organization, 2007.
137. Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, Torre D. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000; 40(3): 282-284.
138. Maron BJ, Seidman JG, Seidman CE. Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 44(11): 2125-2132.
139. Moolman-Smook JC, Mayosi BM, Brink PA, Corfield VA. Molecular genetics of cardiomyopathy: changing times, shifting paradigms. Cardiovasc J S Afr 2003; 14(3): 145-155.
140. Moolman-Smook JC, De Lange WJ, Bruwer EC, Brink PA, Cor-field VA. The origins of hypertrophic cardiomyopathy-causing mutations in two South African subpopulations: a unique profile of both independent and founder events. Am J Hum Genet 1999; 65(5): 1308-1320.
141. Moolman-Smook JC, De Lange J, Brink A, Corfield A. Hypertro-phic cardiomyopathy repealing tenets in South Africa. Cardiovasc J S Afr 2000; 11(4): 202-209.
142. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 1995; 92(7): 1680-1692.
143. Olivotto I, Gistri R, Petrone P, Pedemonte E, Vargiu D, Cecchi F. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41(2): 315-321.
144. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopa-thy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124(24): e783-e831.
145. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342(24): 1778-1785.
146. Sorajja P, Nishimura RA, Ommen SR, Ackerman MJ, Tajik AJ, Gersh BJ. Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. J Am Soc Echocardiogr 2006; 19(6): 788-795.
147. Abegaz B. The impact of echocardiography in the diagnosis of hypertrophic cardiomyopathy. East Afr Med J 1990; 67(8): 556-567.
148. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006; 114(3): 216-225.
149. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287(10): 1308-1320.
150. Turer AT, Samad Z, Valente AM, et al. Anatomic and clinical correlates of septal morphology in hypertrophic cardiomyopathy. Eur J Echocardiogr 2011; 12(2): 131-139.
151. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable car-dioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000; 342(6): 365-373.
152. Maron BJ, Bonow RO, Cannon RO, Leon MB, Epstein SE. Hyper-trophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med 1987; 316(13): 780-789.
153. Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in Africa. Circulation 2005; 112(23): 3577-3583.
154. Mocumbi AO, Ferreira MB, Sidi D, Yacoub MH. A population study of endomyocardial fibrosis in a rural area of Mozambique. N Engl J Med 2008; 359(1): 43-49.
155. Yin R. Endomyocardial fibrosis in China. Chin Med Sci J 2000; 15(1): 55-60.
156. Niino T, Shiono M, Yamamoto T, et al. A case of left ventricular endomyocardial fibrosis. Ann Thorac Cardiovasc Surg 2002; 8(3): 173-176.
157. Schneider U, Jenni R, Turina J, Turina M, Hess OM. Long-term follow up of patients with endomyocardial fibrosis: effects of surgery. Heart 1998; 79(4): 362-367.
158. Davies JN. Endomyocardial fibrosis in Uganda. The Central African J Med 1956; 2(9): 323-328.
159. Davies J, Spry CJ, Vijayaraghavan G, De Souza JA. A comparison of the clinical and cardiological features of endomyocardial disease in temperate and tropical regions. Postgrad Med J 1983; 59(689): 179-185.
160. Connor DH, Somers K, Hutt MS, Manion WC, D'Arbela PG. En-domyocardial fibrosis in Uganda (Davies' disease). 1. An epidemi-ologic, clinical, and pathologic study. Am Heart J 1967; 74(5): 687-709.
161. Beck W, Schrire V. Endomyocardial fibrosis in Caucasians previously resident in tropical Africa. Br Heart J. 1972;34(9):915-918.
162. Sezi CL. Effect of protein deficient cassava diet on Cercopithecus aethiops hearts and its possible role in the aetiology and pathogene-sis of endomyocardial fibrosis in man. East Afr Med J 1996; 73(5 Suppl): S11-S16.
163. Eling WM, Jerusalem CR, Heinen-Borries U. Role of macrophages in the pathogenesis of endomyocardial fibrosis in murine malaria. Trans R Soc Trop Med Hyg 1984; 78(1): 43-48.
164. Rashwan MA, Ayman M, Ashour S, Hassanin MM, Zeina AA. Endomyocardial fibrosis in Egypt: an illustrated review. Br Heart J 1995; 73(3): 284-289.
165. Mocumbi AOH, Ferreira MB. Neglected cardiovascular diseases in Africa challenges and opportunities. J Am Coll Cardiol 2010; 55(7): 680-687.
166. Connor DH, Somers K, Nelson AM, D'Arbela PG, Lukande R. The cause of endomyocardial fibrosis in Uganda. Trop Doct 2012.
167. Freers J, Hakim J, Myanja-Kizza H, E P. The Heart. In: Parry E, Godfrey R, Mabey D, Gill G, editors. Principles of Medicine in Africa. Cambridge: Cambridge Univ Press; 2004.
168. Freers J, Masembe V, Schmauz R, Mayanja-Kizza H. Endomyo-cardial fibrosis syndrome in Uganda. Lancet 2000; 355(9219): 1994-1995.
169. Mohan JC, Jain RK, Khan JA. Endomyocardial fibrosis presenting as recurrent monomorphic ventricular tachycardia as the sole manifestation. Int J Cardiol 1993; 42(1): 89-91.
170. Berensztein CS, Piñeiro D, Marcotegui M, Brunoldi R, Blanco MV, Lerman J. Usefulness of echocardiography and doppler echo-cardiography in endomyocardial fibrosis. J Am Soc Echocardiogr 2000; 13(5): 385-392.
171. Bukhman G, Ziegler J, Parry E. Endomyocardial fibrosis: still a mystery after 60 years. PLoS Negl Trop Dis 2008; 2(2): e97.
172. D'Arbela PG, Mutazindwa T, Patel AK, Somers K. Survival after first presentation with endomyocardial fibrosis. Br Heart J 1972; 34(4): 403-407.
173. Russo PA, Wright JE, Ho SY, Maneksa JR, Clitsakis D. Endo-cardectomy for the surgical treatment of endocardial fibrosis of the left ventricle. Thorax 1985; 40(8): 621-625.
174. Biritwum R, Amoah A, Pobee J. Cardiovascular Diseases in sub-Saharan Africa. Accra, Ghana: ASCOM Publishers; 2005.
175. Pobee J. A view of cardiovascular disease in the African continent. Cardiovascular Epidemiology Newsletter 1979; 26: 23.
176. Isaacson C. The changing pattern of heart disease in South African Blacks. S Afr Med J 1977; 52(20): 793-798.
177. Ogeng'O JA, Gatonga P, Olabu BO. Cardiovascular causes of death in an east African country: an autopsy study. Cardiol J 2011; 18(1): 67-72.
178. Alberts M, Urdal P, Steyn K, et al. Prevalence of cardiovascular diseases and associated risk factors in a rural black population of South Africa. Eur J Cardiovasc Prev Rehabil 2005; 12(4): 347-354.
179. Suliman A. The state of heart disease in Sudan. Cardiovasc J Afr 2011; 22(4): 191-6.
180. Tollman SM, Kahn K, Sartorius B, Collinson MA, Clark SJ, Garenne ML. Implications of mortality transition for primary health care in rural South Africa: a population-based surveillance study. Lancet 2008; 372(9642): 893-901.
181. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 937-952.
182. Steyn K, Sliwa K, Hawken S, et al. Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation 2005; 112(23): 3554-3561.
183. Seedat YK, Mayet FG, Latiff GH, Joubert G. Risk factors and coronary heart disease in Durban blacks--the missing links. S Afr Med J 1992; 82(4): 251-256.
184. Muna WF. The importance of cardiovascular research in Africa today. Ethn Dis 1993; 3 Suppl: S8-S12.
185. Akinkugbe OO, Nicholson GD, Cruickshank JK. Heart disease in blacks of Africa and the Caribbean. Cardiovasc Clin 1991; 21(3): 377-391.
186. Nguchu HK, Joshi MD, Otieno CF. Acute coronary syndromes amongst type 2 diabetics with ischaemic electrocardiograms presenting to accident and emergency department of a Kenyan tertiary institution. East Afr Med J 2009; 86(10): 463-468.
187. Damorou F, Yayehd K, Pessinaba S, Baragou R, Soussou B. Ischemic cardiomyopathy in Lome: epidemiologic aspects and risk factors (study of 461 cases). Mali Med 2008; 23(3): 47-54.
188. Sani MU, Adamu B, Mijinyawa MS, et al. Ischaemic heart disease in Aminu Kano Teaching Hospital, Kano, Nigeria: a 5 year review. Niger J Med 2006; 15(2): 128-131.
189. Ogeng'O JA, Olabu BO, Ong'era D, Sinkeet SR. Pattern of acute myocardial infarction in an African country. Acta Cardiol 2010; 65(6): 613-618.
190. Jablonski-Cohen MS, Kosgei RJ, Rerimoi AJ, Mamlin JJ. The emerging problem of coronary heart disease in Kenya. East Afr Med J 2003; 80(6): 293-297.
191. Vieweg WV, Alpert JS, Johnson AD, et al. Electrocardiographic and left ventriculographic correlations in 245 patients with coronary artery disease. Comput Biomed Res 1980; 13(2): 105-119.
192. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119(14): 1977-2016.
193. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011; 364(17): 1607-1616.
194. Chronic Cor Pulmonale: Report of an Expert Committee. Circulation 1963; 27(4): 594-615.
195. Weitzenblum E, Chaouat A. Cor pulmonale. Chron Respir Dis 2009; 6(3): 177-85.
196. Bloomfield GS, Lagat DK, Akwanalo OC, et al. Conditions that predispose to pulmonary hypertension and right heart failure in persons exposed to household air pollution in LMIC. Global Heart. 2012; 7(3):http://dx.doi.org/10.1016/j.gheart 2012.06.015.
197. Butrous G, Ghofrani HA, Grimminger F. Pulmonary vascular disease in the developing world. Circulation 2008; 118(17): 1758-1766.
198. Aderaye G. Causes and clinical characteristics of chronic cor-pulmonale in Ethiopia. East Afr Med J 2004; 81(4): 202-206.
199. Sliwa K, Carrington MJ, Becker A, Thienemann F, Ntsekhe M, Stewart S. Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. Eur Heart J 2012; 33(7): 866-874.
200. Niakara A, Drabo YJ, Kambire Y, Nebie LV, Kabore NJ, Simon F. Cardiovascular diseases and HIV infection: study of 79 cases at the National Hospital of Ouagadougou (Burkina Faso). Bull Soc Pathol Exot 2002; 95(1): 23-26.
201. Ogeng'O JA, Obimbo MM, Olabu BO, Gatonga PM, Ong'era D. Pulmonary thromboembolism in an East African tertiary referral hospital. J Thromb Thrombolysis 2011; 32(3): 386-391.
202. Lagat D, Carter EJ, Kimaiyo S, Velazques E, Sherman C. The Relationship Of Indoor Air Pollution (iap) Exposure To Isolated Right Heart Failure (irhf) In Women Of Western Kenya: A Pilot Study. Am J Respiratory and Critical Care Med 2012; 185: A1753.
203. Janda S, Shahidi N, Gin K, Swiston J. Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. Heart 2011; 97(8): 612-622.
204. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179(7): 615-621.
205. Okechukwu SO. Pulmonary hypertension in Nigeria. Pulmonary Vasc Res Institute Rev 2010; 2(2): 95.
206. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart J 2009; 30(20): 2493-2537.
207. Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J 2006; 28(5): 999-1004.
208. Mathur PN, Powles P, Pugsley SO, McEwan MP, Campbell EJ. Effect of digoxin on right ventricular function in severe chronic airflow obstruction. A controlled clinical trial. Ann Intern Med 1981; 95(3): 283-288.
209. Voskoboyev AI, Ostrovsky YM. Thiamin pyrophosphokinase: structure, properties, and role in thiamin metabolism. Ann N Y Acad Sci 1982; 378: 161-176.
210. Sole MJ, Jeejeebhoy KN. Conditioned nutritional requirements: therapeutic relevance to heart failure. Herz 2002; 27(2): 174-178.
211. Tobias SL, van der Westhuyzen J, Davis RE, Icke GC, Atkinson PM. Alcohol intakes and deficiencies in thiamine and vitamin B6 in black patients with cardiac failure. S Afr Med J 1989; 76(7): 299-302.
212. Shimon I, Almog S, Vered Z, et al. Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy. Am J Med 1995; 98(5): 485-490.
213. Smithline HA. Thiamine for the treatment of acute decompensated heart failure. Am J Emerg Med 2007; 25(1): 124-126.
214. Herren T, Gerber PA, Duru F. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a not so rare disease of the desmo-some with multiple clinical presentations. Clin Res Cardiol 2009; 98(3): 141-158.
215. Munclinger MJ, Patel JJ, Mitha AS. Follow-up of patients with arrhythmogenic right ventricular cardiomyopathy dysplasia. S Afr Med J 2000; 90(1): 61-68.
216. Watkins DA, Hendricks N, Shaboodien G, et al. Clinical features, survival experience, and profile of plakophylin-2 gene mutations in participants of the arrhythmogenic right ventricular cardiomyopa-thy registry of South Africa. Heart Rhythm 2009; 6(11 Suppl): S10-S17.
217. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33(14): 1787-1847.
218. Goldstein S, Deedwania P, Gottlieb S, Wikstrand J, Group M-HS. Metoprolol CR/XL in black patients with heart failure (from the Metoprolol CR/XL randomized intervention trial in chronic heart failure). Am J Cardiol 2003; 92(4): 478-480.
219. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344(22): 1659-1667.
220. Goldstein S. Beta blocker therapy in African American patients with heart failure. Heart Fail Rev 2004; 9(2): 161-167.
221. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351(20): 2049-2057.
222. Owens AT, Jessup M. The year in heart failure. J Am Coll Cardiol 2012; 60(5): 359-368.
223. Holmes MD, Dalal S, Volmink J, et al. Non-communicable diseases in sub-saharan Africa: the case for cohort studies. PLoS Med 2010; 7(5): e1000244.
224. McCracken JP, Wellenius GA, Bloomfield GS, et al. Household air pollution from solid fuel use: Evidence for links to CVD. Global Heart 2012; 7(3): 223-34.
225. Fonn S. African PhD research capacity in public health raison d'etre and how to build it. Global Forum Health Res 2005; 3: 80-83.
226. Dandel M, Lehmkuhl H, Knosalla C, Suramelashvili N, Hetzer R. Strain and strain rate imaging by echocardiography - basic concepts and clinical applicability. Curr Cardiol Rev 2009; 5(2): 133-148.
227. Choi BG, Mukherjee M, Dala P, et al. Interpretation of remotely downloaded pocket-size cardiac ultrasound images on a web-enabled smartphone: validation against workstation evaluation. J Am Soc Echocardiogr 2011; 24(12): 1325-1330.
228. Fuster V, Kelly BB, Vedanthan R. Global cardiovascular health: urgent need for an intersectoral approach. J Am Coll Cardiol 2011; 58(12): 1208-1210.